→Appendix 1: HIV-protease inhibitors
PDF page 715
▶Uncommon Chest pain. chronic kidney disease.
depression. disorientation. drug reaction with
eosinophilia and systemic symptoms (DRESS). gallbladder
disorders. gynaecomastia. haematuria. memory loss.
myopathy. nephritis tubulointerstitial. nephrolithiasis.
proteinuria. syncope. torsade de pointes. urinary
frequency increased
▶Rare or very rare Gait abnormal. oedema. palpitations.
QT interval prolongation. renal pain. vasodilation
SIDE-EFFECTS, FURTHER INFORMATION Mild to moderate
Infection
rash occurs commonly, usually within the first 3 weeks of
therapy. Severe rash occurs less frequently and may be
accompanied by systemic symptoms. Discontinue if severe
rash develops.
PDF page 715
Theoretical risk of hyperbilirubinaemia in
neonate if used at term.
Monitoring In pregnancy, monitor viral load and plasma-
atazanavir concentration during third trimester.
PDF page 715
Manufacturer advises caution in
mild impairment; avoid in moderate to severe impairment
(no information available).
PDF page 715